Status:
COMPLETED
tDCS to Decrease Opioid Relapse (UG3)
Lead Sponsor:
Butler Hospital
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid Dependence
Craving
Eligibility:
All Genders
21-50 years
Phase:
NA
Brief Summary
In the current proposal, the investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on ...
Detailed Description
Investigators propose to use EEG to examine oscillatory brain changes as well as self-reported craving before and after administration of five sessions of tDCS+Cognitive Control Network (CCN) priming ...
Eligibility Criteria
Inclusion
- current opioid dependence
- between 21-50 years of age
- recent initiation of buprenorphine or methadone (\<30 days)
Exclusion
- current criteria for a DSM-V diagnosis of bipolar disorder, schizophrenia, schizo-affective, schizophreniform, or paranoid disorder
- current suicidality
- evidence of neurocognitive dysfunction
- contraindications for tDCS (e.g seizure disorder)
- probation/parole requirements or an upcoming move that might interfere with protocol participation
- planning to terminate buprenorphine in less than 3 months
- scalp lesions near the tDCS electrode sites
Key Trial Info
Start Date :
June 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2023
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT03842137
Start Date
June 4 2019
End Date
August 31 2023
Last Update
October 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Butler Hospital
Providence, Rhode Island, United States, 02906